Skip to main content
Anaplastic Thyroid Carcinoma, Version 2.2015.
- Haddad, Robert I;
- Lydiatt, William M;
- Ball, Douglas W;
- Busaidy, Naifa Lamki;
- Byrd, David;
- Callender, Glenda;
- Dickson, Paxton;
- Duh, Quan-Yang;
- Ehya, Hormoz;
- Haymart, Megan;
- Hoh, Carl;
- Hunt, Jason P;
- Iagaru, Andrei;
- Kandeel, Fouad;
- Kopp, Peter;
- Lamonica, Dominick M;
- McCaffrey, Judith C;
- Moley, Jeffrey F;
- Parks, Lee;
- Raeburn, Christopher D;
- Ridge, John A;
- Ringel, Matthew D;
- Scheri, Randall P;
- Shah, Jatin P;
- Smallridge, Robert C;
- Sturgeon, Cord;
- Wang, Thomas N;
- Wirth, Lori J;
- Hoffmann, Karin G;
- Hughes, Miranda
- et al.
Published Web Location
http://www.jnccn.org/content/13/9/1140.fullNo data is associated with this publication.
Abstract
This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Thyroid Carcinoma focuses on anaplastic carcinoma because substantial changes were made to the systemic therapy recommendations for the 2015 update. Dosages and frequency of administration are now provided, docetaxel/doxorubicin regimens were added, and single-agent cisplatin was deleted because it is not recommended for patients with advanced or metastatic anaplastic thyroid cancer.
Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.